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Abstract
To evaluate the antigenicity of a peptide representing a part of the second extracellular loop of the human muscarinic
acetylcholine receptor 3 (m3AChR) with autoimmune sera from primary Sjo¨gren’s syndrome (pSS), enzyme-linked immunosorbent
assays (ELISAs) were developed. On the basis of the computer-predicted data, a 16-mer synthetic peptide KRTVPPGECFIQFLSE
(KRSE213e228) was produced by solid-phase peptide synthesis. cDNA coding for the KRSE peptide was chemically synthetized and
utilized to express the recombinant glutathione S-transferase (GST)eKRSE fusion protein. The immunoreactivities of the two
antigens were tested in ELISAs with the sera of 40 pSS patients and 40 healthy controls. The speciﬁcity of the reaction was
conﬁrmed by inhibition assays and immunoblottings.
The pSS sera resulted in signiﬁcantly higher mean optical densities than those of the healthy controls (KRSE: 0.4149 vs 0.1494,
p! 0.0001; GSTeKRSE 0.4765 vs 0.1764, p! 0.0001). The immunological recognition with the recombinant fusion antigen was
signiﬁcantly better than that for the free peptide ( pZ 0.0068). The sensitivities of the assays were 77.5% (KRSE) and 97%
(GSTeKRSE). The results of the concentration-dependent inhibition assays by the two systems of peptide presentation indicated
that the KRSE sequence is speciﬁc for pSS sera. This is the ﬁrst demonstration of the antigenicity of a novel peptide fragment of the
human m3AChR in pSS. The analysed peptide could be of diagnostic relevance.
 2004 Elsevier Ltd. All rights reserved.
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Primary Sjo¨gren’s syndrome (pSS) is a systemic
autoimmune disease. A large number of autoantibodies
have been reported to be frequently present in pSS. In
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doi:10.1016/j.jaut.2004.11.005particular, antibodies to the autoantigens SSA/Ro and
SSB/La, found most commonly in pSS, are used in the
diagnosis of the disease, although these antigens have also
been linked to other autoimmune diseases. The recent
ﬁnding of muscarinic acetylcholine receptor subtype 3
(m3AChR)-speciﬁc autoantibodies in a majority of the
patients is an important advance towards an understand-
ing of the pathogenesis of pSS, as concerns not only the
impaired glandular function, but also the associated
features of an autonomic dysfunction in some patients [1].
The detection of antibodies against the human
m3AChR in the sera of patients with pSS has led to
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The diagnostic signiﬁcance of these antibodies has
therefore remained uncertain.
Synthetic peptides have increasingly been used as
antigens in ELISAs. However, the results are often
inconsistent. Reliable immobilization of the peptides on
a solid support poses diﬃculties, and peptideeplastic
interactions often alter the correct exposure of the
epitopes in a manner that is diﬃcult to predict. Covalent
coupling of the peptides to a carrier protein is therefore
expected to improve the sensitivity of the assays by
providing an appropriate orientation and density of the
epitope [4]. Peptides are often coupled to glutathione S-
transferase (GST) for expression in bacteria as fusion
proteins which are easy to overexpress and purify.
Our previous results involving the use of recombinant
technology for the production of peptides fused to GST
for the diagnosis of bullous pemphigoid support the
advantages of the fusion strategy [5e7].
With regard to the contradictory results of the
detection of m3AChR antibodies by peptide ELISA
and our encouraging experience with the recombinant
fusion peptide, we decided to test whether a novel amino
acid sequence, KRSE213e228, representing a part of the
second extracellular loop of the human m3AChR, is
suﬃciently antigenic to bind autoantibodies from the
sera of pSS patients. For this purpose, we presented the
peptide in two forms, the synthetic peptide and its
recombinant fusion variant, as antigens.
2. Patients and methods
2.1. Patients
Sera were collected from 40 pSS patients (38 females,
2 males, mean age: 55 years, range: 30e82 years). They
all fulﬁlled the AmericaneEuropean classiﬁcation crite-
ria for pSS [8]. Serum samples from 40 healthy blood
donors (mean age: 49 years, range: 23e62 years) served
as controls. All patients gave their informed consent.
The study was approved by the Medical Ethics
Committee of the University of Szeged.
2.2. Computer analysis and peptide synthesis
The sequence of the human m3AChR was from the
Swiss-Prot databank (Acc. No P20309) and the amino
acid sequence (m3AChR191e250) was analysed with the
program ‘‘Peptide Companion’’ Version 1.231 (Coshi-
soft/PeptiSearch).
The peptide sequence of KRTVPPGECFIQFLSE
(KRSE, m3AChR213e228) was synthetized by a solid-
phase technique, utilizing tBoc chemistry [9]. The
peptide chains were elongated on a p-methylhydrylamine
resin (0.48 mmol/g), using an ABI 430A automaticmachine. The crude peptide was puriﬁed by reverse-
phase HPLC and was characterized by mass spectrom-
etry. The detailed procedure is to be found in [6].
2.3. Recombinant techniques
cDNA coding for the KRSE peptide was chemically
synthetized and cloned as described by Molna´r et al. [7].
The recombinant fusion product consists of GST
(pGEX-6P-1, Pharmacia) coupled with the antigenic
peptide at the C-terminus. A dipeptide spacer coded by
the BamHI site used for cloning (Gly-Ser) was inserted
between the GST and the monomeric peptide sequence.
The GST and the recombinant fusion proteins were
expressed in Escherichia coli as described earlier [10].
The fusion protein was puriﬁed over a glutathione-
Sepharose aﬃnity matrix (Pharmacia) from the soluble
fraction of E. coli cell lysate and dialysed against
phosphate-buﬀered saline (PBS, pH 7.4) containing
10 mM dithiotreitol (DTT) before being used for
ELISA.
2.4. Puriﬁcation of anti-KRSE monospeciﬁc
antibody from pSS sera
The GST Orientation kit (Pierce) was used, which
leads to the covalent attachment of the GSTeKRSE
fusion protein to glutathione immobilized on a matrix
(cross-linked 4% beaded agarose). For the covalent
cross-linking of the aﬃnity-puriﬁed GSTeKRSE and
the puriﬁcation of the peptide-speciﬁc antibodies, the
procedure suggested by the instructional manual was
followed.
2.5. PAGE and Western blotting
Expressed and aﬃnity-puriﬁed GST and
GSTeKRSE fusion proteins fractionated by sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) were stained with Coomassie brilliant blue
(Sigma) or transferred to nitrocellulose membrane
(0.2 mm, Schleicher and Schuell). The membrane was
blocked with SuperBlock Blocking Buﬀer (Pierce), and
incubated either with monospeciﬁc antibodies (1:200) or
with patient’s serum (1:500), preincubated with 500 mg/
ml GST in blocking solution. This was followed by
incubation with peroxidase-labelled goat anti-human
IgG (1:10 000, Sigma) and the assay was developed with
3,3#-diaminobenzidine tetrahydrochloride.
The synthetic peptide applied for the ELISA was
either reduced with 50 mM DTT or its cysteine residues
were oxidized in the air. Their electrophoretic mobilities
were analysed by 15% SDSeTricine PAGE [11]. Peptide
was transferred from the gel to nitrocellulose membrane
(0.2 mm). Transfers were carried out according to [12]
with minor modiﬁcations, in 25 mM sodium phosphate
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2 h. The membrane was treated with 0.2% glutaralde-
hyde for 30 min prior to the quenching step in
SuperBlock Blocking Buﬀer. The membrane was reacted
with patient’s serum (1:500) and then handled as
described above.
2.6. ELISA techniques
2.6.1. Peptide ELISA
Eight microgram per well peptide in 100 ml of PBS,
pH 7.4, was used to coat microtitre plates (ThermoLabs,
Cat. No 95029100) at 4 C overnight. After coating, the
plates were washed with PBS and blocked with
SuperBlock Blocking Buﬀer for 1 h at room tempera-
ture. Duplicate serum samples from pSS or from healthy
individuals were diluted (1:50) in blocking solution and
incubated for 2 h at 37 C. After washing, horseradish
peroxidase-labelled goat anti-human IgG antibody
(1:10 000, Sigma) in blocking solution was added and
the mixture was incubated for 1 h at 37 C. The reaction
was developed with o-phenylenediamine in phosphate-
citric acid buﬀer, pH 5.0, for 30 min at room temper-
ature in the dark; the development was stopped with 4 N
sulfuric acid. The absorbance values were measured at
492 nm. Strongly positive patient’s serum or aﬃnity-
puriﬁed anti-KRSE monospeciﬁc antibodies were used
as positive controls. The results for each sample were
expressed as the means of the duplicate values for the
sera minus the background values.
2.6.2. Recombinant fusion peptide ELISA
The quantities of antigens used for coating were
equalized to the GST portion of the fusion partner.
Microtitre plates were coated overnight at 4 C with
0.9 mg/well GST and 1 mg/well GSTeKRSE in 100 ml of
0.1 M Na2CO3 buﬀer, pH 9.6, containing 10 mM DTT.
The test sera were diluted 1:100. All subsequent steps of
the procedure were carried out as described above for
the peptide-ELISA. The speciﬁc corrected optical
densities (ODs) of individual positive and negative
samples were calculated by subtracting the OD for the
GST protein from that for the GSTeKRSE fusion
protein.
2.7. Inhibition assays
2.7.1. Inhibitions by peptide
Five strongly positive patient’s sera were used at
a dilution of 1:50 in SuperBlock Blocking Buﬀer
containing the inhibiting KRSE synthetic monomer
peptide at 500 mg/ml. Concentration-dependent inhibi-
tion was also tested by two representative sera from the
ﬁve at a dilution of 1:100 in the range from 0 to 200 mg/
ml of monomer KRSE peptide. As an irrelevant peptide,
PGSTFERKTHVTRHAYEG (PGEG129e146) was used,which is a part of the bullous pemphigoid antigen 180:
AC Q 02802. After preincubation (1 h at 37 C and then
overnight at 4 C), the sera were tested for their activity
against KRSE by peptide-ELISA, as described above.
2.7.2. Inhibitions by recombinant fusion peptide
Another two representative sera from the ﬁve were
used at a dilution of 1:200 containing the inhibiting
GSTeKRSE, GST and GSTePGEG antigens over the
range from 0 to 200 mg/ml. In the presence of
GSTeKRSE and GSTePGEG as competitor antigens,
the incubation mixtures also contained 500 mg/ml of
GST for the competition of the anti-GST antibodies.
After preincubation (2 h at room temperature), the sera
were tested for their activity against GSTeKRSE as
described in the ELISA methods.
The percentage inhibition of the antibody binding to
the KRSE was calculated as [1(absorbance after
preincubation/absorbance without preincuba-
tion)]! 100. The sera were tested in duplicate; the
individual ODs and the average of the OD values for 5
positive sera were used for calculation.
2.8. Statistical analysis
Cut-oﬀ values were calculated as cC 2SD (where c
was the mean OD for the control subjects). For
assessment of whether the mean values of the groups
were signiﬁcantly diﬀerent, Student’s t-test was used,
while for the comparison of frequencies, the c2 test was
applied. A value of p! 0.05 was considered signiﬁcant.
The sensitivity and the speciﬁcity of the method were
calculated in the standard fashion.
3. Results
3.1. Computer analysis
Fig. 1 presents the secondary structure prediction and
some other predicted parameters (hydrophilicity, acces-
sibility and antigenicity) for the extracellular
m3AChR213e228 amino acid sequence. The Chou Fas-
man method predicts an N-terminal prominent turn (5
residues), a 10 amino acid region closer to the C-
terminus with a preference for helix formation and an
intervening sheet (5 residues). The accessibility, hydro-
philicity and antigenicity proﬁles indicate that the
framed region seems to have the best propensity for
antibody binding as concerns the analysed sequence.
3.2. ELISA techniques
The computer-predicted synthetic KRSE peptide was
passively adsorbed onto the plate to evaluate its
reactivity with the pSS sera. We failed to detect
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bodies when it was used in reduced (monomer) form
(data not shown). However, when oxidation of the
peptide occurs under aerobic conditions, dimerization
proceeds through the cysteine residues, and we could
detect autoantibodies with ODs above the background
(Fig. 2A). The sera of 0/40 of the healthy controls and
31/40 of the pSS patients gave positive peptide-speciﬁc
reactions. The sensitivity of the test system proved to be
77.5%. The electrophoretic mobilities of the reduced
and oxidized forms of the synthetic peptide used for
ELISA are shown in Fig. 3I.
Scatter plot diagrams of the reactivities of the pSS
and the healthy control sera with the fusion
GSTeKRSE antigen are depicted in Fig. 2B. The sera
D
C
B
A sheet
helix
turn
Fig. 1. Computer-assisted analysis of the human m3AChR191e250
sequence. (A) Potential of helix, sheet and turn formation according to
the Chou Fasman algorithm, (B) the Hopp and Woods hydrophilicity
scale, (C) the Janin accessibility scale, and (D) the Welling et al.
antigenicity scale. The framed part of the sequence was used for the
experimental work.of 0/40 of the healthy controls and 39/40 of the pSS
patients gave positive peptide-speciﬁc reactions, with
97% sensitivity. In a separate experiment, 25/40 pSS
patients were positive for either anti-SSA or anti-SSB
antibodies, with a sensitivity of 72% using the same
collection of sera (not shown).
The above data were analysed to compare the
immunoreactivities in the two ELISA systems (Fig. 2C
and D). In both ELISA systems, signiﬁcant diﬀerences
were observed between the pSS and healthy groups, but
the proportion of pSS patients positive for anti-
m3AChR antibodies was higher with the recombinant
fusion peptide as antigen (39/40 vs 31/40, pZ 0.0068).
The distributions of the ODs in the positive range also
diﬀered: with the peptide ELISA, apart from 5 out-
standingly high values, the results clustered in the low
positive range (ODs between the cut-oﬀ and 0.4), while
with the GSTeKRSE assay, a signiﬁcantly higher
proportion of the values were in the higher range
(ODO 0.4: 23/40 vs 12/40 with the GSTeKRSE and
KRSE ELISA, respectively, pZ 0.0214).
3.3. Inhibition and immunoblot assays
To verify the speciﬁcity of the immune reaction, 50-
fold dilutions of 5 strongly positive sera were preincu-
bated with the KRSE peptide prior to the peptide-based
ELISA, separately. Fig. 4I, A shows that, after
preincubation with the peptide at 500 mg/ml, the
inhibitions of the respective sera were 75%, 60%,
70%, 71% and 68%. The average ELISA reactivity of
these sera was reduced by w70%, demonstrating
a peptide-speciﬁc inhibition. A similar inhibition was
not observed for the healthy controls (not shown).
Maximum inhibitions of 62% and 54% were observed
with sera numbers 2 and 1 in the range 0e200 mg/ml
KRSE (Fig. 4I, B). Sera 3 and 5 exhibited maximum
inhibitions of 63% and 71%, respectively, with the
GSTeKRSE inhibitor protein (Fig. 4II, C,D). These
values were signiﬁcantly higher than those for the
irrelevant peptide (KRSE vs PGEG: 63% and 71% vs
8% and 9%, p! 0.0001 in both cases).
Immunoblot analysis of the monospeciﬁc antibodies
puriﬁed from the pSS sera also indicated sequence-
speciﬁc binding to the GSTeKRSE fusion protein; no
reaction was observed with GST alone (Fig. 3II, panel
B). Additionally, non-puriﬁed pSS sera were examined
by immunoblottings with GST, and with the
GSTeKRSE and KRSE antigens, and sequence-speciﬁc
immunoreactions were also observed at serum dilutions
of 1:500 (Fig. 3I, lane WB, and 3III).
4. Discussion
An important new ﬁnding with regard to the
pathogenesis of pSS was the detection of autoantibodies
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Fig. 2. Detection of autoantibodies against the human m3AChR by enzyme-linked immunosorbent assay (ELISA). (A) and (B) The scatterograms
show the individual optical density (OD) values for each serum sample at dilutions of 1:50 and 1:100, respectively, for the pSS and healthy control
groups. Solid lines: cut-oﬀ values (mean ODsC 2SD for the healthy controls); dotted lines: median ODs for pSS patients (C). Bars represent the
meansG SEM of the immunoreactivities of the two groups of tested sera. p-values between the groups are indicated. (D) Distribution of the positive
sera in three OD ranges. Bars represent the number of sera (giving in percentage) in the given range with the KRSE or GSTeKRSE antigens.directed against the m3AChR. The presence of these
autoantibodies has been conﬁrmed in functional assays
in animals [13e15], but their existence in patients with
pSS remained controversial when ELISA methods were
used.
Cavill et al. [3] applied peptide-ELISA systems for the
detection of autoantibodies to the human m3AChR in
pSS, but failed to observe immune activity with either
a 20-mer (m3AChR208e227) or a 25-mer (m3AChR213e237)
synthetic peptide.In the present work, we set out to ﬁnd a more reliable
antigenic peptide sequence for the assessment of
immunological activity. Accordingly, we applied com-
puter programs to analyse the structural preferences and
physicochemical properties of a 60 amino acid sequence
(m3AChR191e250) of the human m3AChR which spans
the second extracellular loop. From a consideration of
parameters such as antigenicity, accessibility and hy-
drophilicity, features characteristic of antibody-binding
sites and secondary structure preferences, our choice
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Fig. 3. Sodium dodecylsulfate-polyacrylamide gel electrophoresis (PAGE) and Western blotting of the KRSE peptide, GST and GSTeKRSE
proteins. (I) KRSE peptide in reduced (lane 1) or oxidized (lane 2) form was run in 15% PAGE-Tricine, and stained with Coomassie brilliant blue.
(WB) Immunoreaction of the monomer KRSE peptide with a patient’s serum at a dilution of 1:500. (II) Twelve percent PAGE of the aﬃnity-puriﬁed
GST (lanes 2) and GSTeKRSE (lanes 1) antigens (A). Coomassie brilliant blue-stained gel. Immunoreactions of the same antigens with the anti-
KRSE monospeciﬁc antibodies (B), and antibodies found in the ﬂow-through of aﬃnity chromatography (1:200) (C). III. Coomassie brilliant blue
staining (1) and immunoreactions of the GST and GSTeKRSE antigens with a representative pSS serum with (2) or without (3) preincubation in the
presence of 500 mg/ml GST. Ten microgram per samples were analysed.narrowed down to a 16-mer fragment (m3AChR213e228),
positioned exclusively extracellularly, and we tested its
antigenicity in the pSS and healthy control groups. We
could detect an immune reaction in peptide ELISAs
only if the peptide was dimerized through disulﬁde
bond formation by the only cysteine residue within the
KRSE. In addition to the advantageous physicochem-
ical property of the KRSE peptide sequence, we
explain the above phenomenon with the fact that,
under dimer conditions, one of the two KRSE
sequences is appropriately exposed, so that improved
binding with the patient’s antibodies can occur. This is
supported by the peptide inhibition assay, where the
competitor monomeric reduced peptide in soluble form
inhibited the immunological recognition perfectly in
a concentration-dependent way.
In order to optimize the peptide presentation for
recognition by autoantibodies and to avoid the rather
problematic peptide-based ELISA system, we fused the
antigenic peptide to the GST carrier protein. This formof presentation increased the antigenicity of the peptide,
as demonstrated by the 97% sensitivity of this assay.
With reference to our conformational studies on this
topic [6], we suggest that the higher eﬃciency and
ﬁdelity of the GSTeKRSE fusion product are due to the
avidity eﬀect of GST dimer formation and to the
beneﬁcial local conformational consequences. A more
standard coating of the fusion antigen also contributed
to a more reliable and reproducible immunoassay.
Taken together, the speciﬁcity of the immunoreactiv-
ity of the KRSE sequence was conﬁrmed by several
techniques, including standard ELISAs and competitive
binding ELISAs. Western blottings oﬀered further
evidence of the speciﬁcity of the pSS patient’s antibodies.
In summary, we have identiﬁed a novel antigenic
peptide of human m3AChR. The antigenicity of this
peptide was tested empirically in two presentation
forms, the synthetic peptide and the recombinant fusion
protein, by ELISA. The immunoreactivity of the fusion
antigenic KRSE213e228 peptide with pSS patients’ sera
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